Ono T, Uenaka A, Nakayama E
Department of Parasitology and Immunology, Okayama University Medical School, Shikata-cho.
Jpn J Cancer Res. 1996 Nov;87(11):1165-70. doi: 10.1111/j.1349-7006.1996.tb03127.x.
In this study, we demonstrated that NH2-terminal Ser and Ile residues of pRL1b (SI-pRL1a) (SIIPGLPLSL) are not involved in the recognition by RLmale 1-specific cytotoxic T lymphocyte. The sensitization activity observed with pRL1b (SI-pRL1a) was not greater than that of peptides substituted with irrelevant amino acids at these positions. In serum-free medium, pRLla retained sensitization activity, but pRL1b (SI-pRL1a) did not. Furthermore, addition of bestatin to serum-containing medium blocked sensitization by pRL1b (SI-pRL1a). On the other hand, the addition of captopril enhanced it, probably by inhibiting the degradation of pRL1a by ACE. pRL1a-D peptide with D-Ile in place of the L-Ile residue of pRL1a (IPGLPLSL) showed sensitization, but SI-pRLla-2,3D peptide, which has D-Iles in place of the L-Ile residues of pRLlb (SI-pRL1a), and which was not cleaved between the two D-Iles, did not. The findings suggest that pRL1a is the antigenic peptide bound to L(d) molecules and pRL1b (SI-pRL1a) peptide is its natural precursor, which generates pRL1a via proteolysis.
在本研究中,我们证明了pRL1b(SI-pRL1a)(SIIPGLPLSL)的氨基末端丝氨酸和异亮氨酸残基不参与RLmale 1特异性细胞毒性T淋巴细胞的识别。用pRL1b(SI-pRL1a)观察到的致敏活性不高于在这些位置被无关氨基酸取代的肽的致敏活性。在无血清培养基中,pRLla保留致敏活性,但pRL1b(SI-pRL1a)则不然。此外,向含血清培养基中添加贝司他汀可阻断pRL1b(SI-pRL1a)的致敏作用。另一方面,添加卡托普利可增强致敏作用,可能是通过抑制ACE对pRL1a的降解。用D-异亮氨酸取代pRL1a(IPGLPLSL)的L-异亮氨酸残基的pRL1a-D肽显示出致敏作用,但SI-pRLla-2,3D肽(用D-异亮氨酸取代pRLlb(SI-pRL1a)的L-异亮氨酸残基且在两个D-异亮氨酸之间未被切割)则没有。这些发现表明,pRL1a是与L(d)分子结合的抗原肽,而pRL1b(SI-pRL1a)肽是其天然前体,通过蛋白水解产生pRL1a。